Today: 2 March 2026
Subscribe
Browse Category

Mergers & Acquisitions 8 November 2025 - 12 November 2025

Baytex Energy (BTE.TO) Sells Eagle Ford Assets for US$2.305 Billion; Stock Jumps After CIRO Halt — Nov. 12, 2025

Baytex Energy (BTE.TO) Sells Eagle Ford Assets for US$2.305 Billion; Stock Jumps After CIRO Halt — Nov. 12, 2025

Baytex Energy will sell its entire U.S. Eagle Ford business for US$2.305 billion in cash to an undisclosed buyer. The company plans to repay debt and boost shareholder returns, shifting focus to Canadian oil assets. Trading in Baytex shares was briefly halted before rising on the Toronto Stock Exchange. Deal closing is expected in late 2025 or early 2026, pending approvals.
12 November 2025
·····
BILL Holdings (BILL) Surges as Company Explores a Sale — What Investors Need to Know Today (Nov. 12, 2025)

BILL Holdings (BILL) Surges as Company Explores a Sale — What Investors Need to Know Today (Nov. 12, 2025)

BILL Holdings shares jumped 13% to $52.68 after reports said the company is exploring a possible sale with help from financial advisers. Talks are in early stages, with no guarantee of a deal. The review follows activist pressure from Starboard Value, which took an 8.5% stake and prompted board changes in October. BILL has not commented on the process.
12 November 2025
··
Clearwater Analytics (CWAN) Weighs Sale; Shares Jump as Wellington Files 6.2% Stake and New Report Flags $2.7T Insurance ‘Alts’ Shift

Clearwater Analytics (CWAN) Weighs Sale; Shares Jump as Wellington Files 6.2% Stake and New Report Flags $2.7T Insurance ‘Alts’ Shift

Clearwater Analytics shares jumped about 8.6% Wednesday after Bloomberg reported the company is weighing a potential sale following takeover interest. Wellington Management disclosed a 6.2% passive stake in a new SEC filing. Clearwater also released a study showing U.S. insurers now hold $2.7 trillion in alternative assets.
12 November 2025
··
CMCT Sells Lending Arm to Peachtree Affiliate for ~$44M; Stock Jumps, CFO Transition Set — Nov. 12, 2025

CMCT Sells Lending Arm to Peachtree Affiliate for ~$44M; Stock Jumps, CFO Transition Set — Nov. 12, 2025

Creative Media & Community Trust Corporation agreed to sell its lending division, First Western SBLC, Inc., to a Peachtree Group affiliate for about $44 million, pending SBA approval. CMCT expects roughly $31 million in net cash after debt and fees. CFO Barry Berlin will resign at closing, with Brandon Hill set to take over. Shares jumped over 70% intraday following the announcement.
12 November 2025
···
Salarius Pharmaceuticals (SLRX) Stock Jumps as $7M Offering Prices; Closing Expected November 12, 2025 Amid Decoy Therapeutics Merger

Salarius Pharmaceuticals (SLRX) Stock Jumps as $7M Offering Prices; Closing Expected November 12, 2025 Amid Decoy Therapeutics Merger

Salarius Pharmaceuticals priced a $7 million underwritten public offering, with closing contingent on its merger with Decoy Therapeutics. The deal includes common shares, pre-funded warrants, and fixed-price Series A and B warrants. Shares plunged up to 51% Tuesday after the financing news, then rebounded over 50% pre-market and up to 65% intraday today. The merger is expected to close around November 12, 2025.
12 November 2025
···
Coinbase (COIN) Stock Crashes in Crypto Sell-Off – Can It Bounce Back?

Coinbase Walks Away From $2 Billion BVNK Deal as UK Weighs Strict Stablecoin Caps

Coinbase and BVNK ended exclusive talks over a $2 billion acquisition, a Coinbase spokesperson confirmed. The decision comes days after the Bank of England proposed holding caps and reserve requirements for sterling stablecoins, drawing criticism from industry groups. Fortune first reported the deal’s collapse. BVNK had raised $50 million last December at a $750 million valuation.
12 November 2025
···
Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer (PFE) Today — Nov. 11, 2025: $10B Metsera Deal Nears Vote, Oncology Game Plan Expands, Shares Rise

Pfizer will acquire Metsera for up to $10 billion, offering $65.60 per share in cash plus contingent value rights, with a shareholder vote set for Nov. 13. Metsera’s board favored Pfizer over Novo Nordisk after FTC antitrust concerns tipped the balance. Pfizer shares rose about 4–5% to $25.50 following the news. The company also announced seven new trials for its PD‑1×VEGF bispecific antibody, including a phase 3 lung cancer study.
11 November 2025
···
Paramount Skydance (NASDAQ: PSKY) Jumps on First Post‑Merger Earnings: $1.5B Content Push, $3B Cost Cuts, Paramount+ Price Hike — 11/11/2025

Paramount Skydance (NASDAQ: PSKY) Jumps on First Post‑Merger Earnings: $1.5B Content Push, $3B Cost Cuts, Paramount+ Price Hike — 11/11/2025

Paramount Skydance shares jumped 5.5% after the company raised its annual cost-savings target to $3 billion and announced over $1.5 billion in new programming spend for 2026. Q3 revenue was about $6.7 billion with a net loss of $257 million. Paramount+ will raise U.S. prices in January 2026. Around 600 employees exited under a new return-to-office policy, with further cuts expected from asset sales in Argentina and Chile.
11 November 2025
··
Kaltura (KLTR) soars as Q3 beats, $27M eSelf.ai deal lands, and 14.4M-share buyback headlines — Nov. 11, 2025

Kaltura (KLTR) soars as Q3 beats, $27M eSelf.ai deal lands, and 14.4M-share buyback headlines — Nov. 11, 2025

KLTR shares surged as much as 24% after Kaltura reported Q3 revenue of $43.9M and announced a $27M deal to acquire eSelf.ai. The company posted record adjusted EBITDA of $4.2M and repurchased 14.4M shares from Goldman Sachs at a 25% discount. Closing of the eSelf.ai acquisition is expected in Q4 2025.
11 November 2025
····
C3.ai (AI) shares edge higher as company explores sale — everything new on November 11, 2025

C3.ai (AI) shares edge higher as company explores sale — everything new on November 11, 2025

C3.ai shares rose nearly 4% premarket after Reuters reported the company has started an early-stage sale process and may seek private capital, citing unnamed sources. The move follows a leadership change and the withdrawal of full-year guidance in September. C3.ai posted a 19% revenue drop in fiscal Q1 and a net loss of $116.8 million. The company did not comment on the report.
11 November 2025
····
Shiseido cuts 2025 outlook to ¥52bn net loss, books ¥46.8bn Americas impairment and launches 200‑person voluntary exit

Shiseido cuts 2025 outlook to ¥52bn net loss, books ¥46.8bn Americas impairment and launches 200‑person voluntary exit

Shiseido cut its full-year forecast to a ¥52 billion net loss, citing a ¥46.8 billion goodwill impairment in its Americas business and weaker demand. The company lowered revenue guidance by ¥30 billion to ¥965 billion and announced 200 voluntary retirements in Japan. Dividend guidance remains unchanged at ¥40 per share. Nine-month net sales fell 4% to ¥693.8 billion.
10 November 2025
·
Axia Energia debuts AXIA3; court declares Oi bankrupt; Kepler Weber gets R$11 offer — Brazil market wrap (Nov 10)

Axia Energia debuts AXIA3; court declares Oi bankrupt; Kepler Weber gets R$11 offer — Brazil market wrap (Nov 10)

Oi was declared bankrupt by the 7th Business Court of Rio de Janeiro; telecom services will continue temporarily under court supervision as assets are liquidated. Axia Energia began trading under new tickers on B3 and NYSE, with AXIA3 rising 1.84% by mid-morning. Kepler Weber received a non-binding R$11 per share offer from GPT, a 48.3% premium to the 60-day VWAP.
10 November 2025
····
Metsera (MTSR) Sinks as Pfizer Seals Revised $10B Buyout; 8‑K Spells Out $65.60 Cash + Up to $20.65 CVR — Nov. 10, 2025

Metsera (MTSR) Sinks as Pfizer Seals Revised $10B Buyout; 8‑K Spells Out $65.60 Cash + Up to $20.65 CVR — Nov. 10, 2025

Metsera shares fell about 15% Monday after the company accepted Pfizer’s revised takeover offer, ending a bidding war with Novo Nordisk. Pfizer will pay $65.60 per share in cash plus up to $20.65 in contingent value rights. Novo withdrew its bid over the weekend. Metsera cited U.S. FTC antitrust concerns with Novo’s proposal.
10 November 2025
····
Movano (NASDAQ: MOVE) Soars on All‑Stock Merger With Corvex to Create Secure AI‑Infrastructure Pure Play — Nov. 10, 2025

Movano (NASDAQ: MOVE) Soars on All‑Stock Merger With Corvex to Create Secure AI‑Infrastructure Pure Play — Nov. 10, 2025

Movano and Corvex, Inc. agreed to merge in an all-stock deal, with Corvex holders owning about 96% of the combined company. The new entity, to be called Corvex, Inc., will focus on AI infrastructure and be based in Arlington, VA. Corvex raised $37.1 million in concurrent financing; Movano secured a $1 billion equity facility and $3 million bridge loan. MOVE shares jumped intraday after the announcement.
10 November 2025
···
Ondas Holdings (ONDS) names ex‑Rafael chief Yoav Har‑Even to OAS advisory board as Sentrycs acquisition advances — Nov. 10, 2025

Ondas Holdings (ONDS) names ex‑Rafael chief Yoav Har‑Even to OAS advisory board as Sentrycs acquisition advances — Nov. 10, 2025

Ondas Holdings named Maj. Gen. (Ret.) Yoav Har‑Even, ex-CEO of Rafael Advanced Defense Systems, to the advisory board of its defense robotics unit. The company reported record 2025 international orders for its Optimus drone and Iron Drone Raider platforms. Shares rose about 10.5% to $5.81 Monday afternoon. Ondas expects its Sentrycs acquisition to close in November 2025.
10 November 2025
·
Pfizer Stock 2025: 7% Dividend, Obesity Gamble, and Wall Street’s Verdict

Novo Nordisk and Pfizer Stocks Today (Nov. 10, 2025): Pfizer Clinches $10B Metsera Deal as Novo Rises on Exit and India Brand Move

Pfizer will acquire obesity drug developer Metsera in a deal worth up to $10 billion, with a shareholder vote set for Nov. 13. Novo Nordisk shares rose after it exited the bidding. Norway’s $1.5 trillion sovereign wealth fund said it will abstain from voting on Novo’s new board at a meeting Nov. 14. Novo also signed a deal to distribute its semaglutide weight-loss shot in India under the brand Poviztra.
10 November 2025
··
Pandox Completes €1.7bn Dalata Takeover: Dalata Delists Today as Scandic Takes Over 56 Hotels (10 Nov 2025)

Pandox Completes €1.7bn Dalata Takeover: Dalata Delists Today as Scandic Takes Over 56 Hotels (10 Nov 2025)

Dalata Hotel Group was delisted Monday after its €1.7 billion acquisition by a Pandox–Eiendomsspar consortium. Scandic Hotels Group has taken over management of Dalata’s 56 hotels and plans to buy the operating platform for €500 million after a carve-out. Pandox will retain 31 properties in Ireland and the UK under long-term leases. Shareholder payouts are due by 21 November.
10 November 2025
··
Bristol‑Myers Squibb (BMY) today: €5B euro‑notes closing, $239M Celgene suit settlement, BioNTech cash flows lift guidance — what to watch on November 9, 2025

Bristol‑Myers Squibb (BMY) today: €5B euro‑notes closing, $239M Celgene suit settlement, BioNTech cash flows lift guidance — what to watch on November 9, 2025

Bristol Myers Squibb priced €5 billion in senior notes across five tranches, with closing expected Nov. 10; proceeds will fund a debt tender offer running through Dec. 3. The company agreed to a $239 million settlement in a Celgene class action, pending court approval. BioNTech raised its 2025 revenue outlook after receiving payments from a new BMS alliance. FDA approved a generic for Sprycel on Nov. 7.
9 November 2025
··
Metsera (NASDAQ: MTSR): Pfizer Clinches $10B Deal as Novo Nordisk Bows Out — What to Know Today (Nov. 8, 2025)

Pfizer Clinches $10B Takeover of Metsera as Novo Nordisk Bows Out — Full Terms, Timeline, and What It Means (Nov. 8, 2025)

Metsera agreed to Pfizer’s revised takeover offer worth up to $10 billion after Novo Nordisk withdrew from bidding. The deal values Metsera at $86.25 per share, including $65.60 in cash and up to $20.65 via a contingent value right. Metsera shareholders will vote on the merger November 13. Both companies expect a swift closing if approved.
8 November 2025
····
1 … 13 14 15 16 17 … 20
Go toTop